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The ability to replace faulty body parts with trans-
planted cells, tissues, and organs has forever altered the 
principles guiding the practice of medicine. I will first 
describe how basic science played an essential role in this 
revolution. But my second objective will be to show how 
surgeons successfully violated the preexisting rules of 
immunology and biology, thereby endowing transplan-
tation with an enduring element of mystery. In the long 
run, surgeons who created the mystique also removed it, 
but not until a third of a century later. 
THE DAWN OF MODERN TRANSPLANTATION: 
1953 TO 1968 
The basis for the scientific mystery can be understood 
only from a historic perspective. The chain of events 
began during the Battle of Britain when a 24-year-old 
Oxford zoologist named Peter Medawar was assigned to 
wartime duty with the Scottish plastic surgeon, Tom 
Gibson. The purpose of the alliance between the prac-
ticing surgeon and the basic scientist was to determine if 
skin from cadavers could be used to treat fire bomb 
victims of the Battle of Britain. The results of their stud-
ies, which were first clone in humans and then confirmed 
in animals, showed that rejection of the skin is an im-
mune reaction. 1,2 
The key observation came from experiments in which 
repeated skin grafts were transplanted from the same 
donor to a given recipient, placing each graft after the 
preceding one had been rejected. The transplants had a 
decremental survival. For example, the time to rejection 
might be 10 days for a first graft, 5 days for the next one 
from the same donor, and only a few hours after four or 
five preceding grafts (Fig. 1). Although immunology was 
still an infimt'science, this circumstantial evidence that 
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rejection was an immune response prompted surgeons 
of the 1940s and early 1950s to envision mitigation of 
the response with total body irradiation. Experiments in . 
animals included kidney and skin transplantation. Irra-
diation had no effect on graft survival but the modern 
era of transplantation was just around the corner. 
; . The beginning of the modern era is usually dated to a 
brief report that appeared in me October 3, 1953 issue 
of the journal, Nature. 3 The authors were Rupert 
Billingham, Leslie Brent, and the war-time investigator 
Peter Medawar, who by now was 34 years old. The men, 
who soon would be known as the "holy trinity" of trans-
plantation immunology, described how they had iso-
lated the leukocytes from the spleen or bone marrow of 
adult mice and injected these donor cells into the blood 
of newborn mouse recipients. Because the immune sys-
tem of newborn mice was not yet developed enough to 
reject the infused cells, the donor leukocytes engrafted 
and were thought to have replaced the recipient immune 
cells (Fig. 2, outer cycle). This condition is known as 
complete donor leukocyte chimerism. 
By 1955, similar leukocyte chimerism was produced 
in Bethesda at the National Institutes of Health cancer 
division, but this time, in adult mouse recipients whose 
otherwise normal immunity had been weakened by total 
body irradiation4 (Fig. 2, inner cycle). Once the donor 
leukocytes were engrafted, both the neonatal and irradi-
ated adult mice were able to accept skin or other tissues 
from the original leukocyte donors but from no other 
donor. These were the first examples in the world of 
acquired donor-specific transplantation tolerance. The 
tolerance was clearly associated with the presence of do-
nor leukocyte chimerism. 
To surgeons, the logical next step appeared to be pro-
duction of leukocyte chimerism by bone marrow trans-
plantation before or at the same time as organ transplan-
tation from the same donor. In 1958, John Mannick,5 
then working in Cooperstown, NY, was able, with this 
strategy, to avoid canine kidney allograft rejection. But 
prolonged recipient survival could be accomplished only 
in a single beagle dog who lived. for 70 days before dying 
of pneumonia. It also had become clear that avoidance of 
graft rejection would not be the only problem with co-
ISSN 1072-7515/05/$30.00 
dOi:l0.l016/j.jamcollsurg.2005.03.023 
..... 
I 
j 
(. 
Vol. 201, No.2, August 2005 
1st graft 
2nd graft 
3rct graft 
4th graft 
5 10 
Days of skin Graft Survival 
Figure 1. Peter Medawar's experiment showing that when skin from 
the same donor is repetitively transplanted to a given recipient, graft 
survival becomes progressively shorter. This was convincing evi-
dence that graft rejection is an immune response. (Reprinted from: 
Starzl TE. Organ transplantation: a practical triumph and episte-
mologic collapse. Proc Am Philos Soc 2003;147:226-245, with 
permission.) 
transplantation of bone marrow cells and an organ. In 
1956, Medawar's associates, Billingham and Brent,6 and 
the Danish scientist, Morten Simonsen/ had shown that 
the successfully engrafted donor leukocytes could rurn 
the tables and reject the recipients (graft-versus-host dis-
ease). This lethal complication could be avoided in the 
mouse tolerance models only if the donor and recipient 
had a good tissue match. 
FIRST SUCCESSFUL CLINICAL BONE 
MARROW TRANSPLANTATION 
Human tissue antigens (so-called HLA antigens) had 
not yet been. discovered and would not be delineated 
well enough for another decade to permit the obligatory 
donor-to-recipient matching. After overcoming this ob-
stacle, bone marrow transplantation was finally accom-
plished in 1968.8•9 The escalation from the original 
mouse tolerance model of 1953 to the first successful 
human bone marrow transplantations of 1968 was her-
alded as an ideal example of "translational" research. The 
drug-free HLA-matched humans, with their leukocyte 
chimerism and acquired tolerance were perfect ana-
logues of the animals. But this would not be the means 
to the end of organ transplantation that surgeons had 
envisioned. Instead, bone marrow transplantation was 
destined to become a definitive treatment for immune 
deficiency diseases, blood disorders, and numerous 
other conditions. 10 
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Figure 2. The mouse models of acquired tolerance described be-
tween 1953 and 1955.3.4 White cells (leukocytes) were isolated 
from the spleen or bone marrow of adult donor mice (upper left), and 
injected into the bloodstream of newborn mice (outer cycle), or of 
irradiated adult mice (inner cycle). Under both circumstances, the 
recipient immune system was too weak to reject the foreign cells 
(dark shaded). With engraftment of the injected cells (ie, donor 
leukocyte chimerism), the recipient mice now could freely accept 
tissues and organs from the leukocyte donor, but from no other 
donor (bottom left). Clinicians interested in organ transplantation 
promptly envisioned the use of bone marrow cell transplantation as 
a preparatory step to organ transplantation. 
SUCCESSFUL TRANSPLANTATION 
OF ORGAN ALLOGRAFTS 
In the meanwhile, renal transplantation in humans ll 
had become a widely used clinical service (albeit a flawed 
one) and by 1968 the first successful liver12 and heart 
transplantations13 also had been reported (Table 1). In 
contrast to the "bench to bedside" sequence of bone 
marrow transplantation, successful implantation of kid-
ney allografts was accomplished initially in humans 
rather than in animals, first in Boston by Joseph E Murrayll 
inJanuary 1959 and then 5 months later by Jean Hanl-
burgerl4 in Paris (Table 2). In these two patients, frater-
nal twin kidneys were transplanted into recipients who 
had been conditioned with sublethal total body irradia-
tion without donor bone marrow infusion. 11 ,14.15 
Drug immunosuppression was not yet available. Nev-
Table 1. First Successful Transplantation of Human Allo-
grafts (Survival ~ 1 Year) 
organ City (ref) Date Physician/surgeon 
Kidney Boston (11) 1124/59 Murray 
Liver Denver (I 2) 7/23/67 Stan] 
Heart Cape Town (13) 112/68 Barnard 
Bone marrow Minneapolis (8) 8/24/68 Good 
I 
I 
162 Starzl Mystique of Organ Transplantation J Am Coli Surg 
Table 2. Kidney Transplantation 2:: 6 Months Survival as of March 1963 
Patient no. City (Ref) Date Donor Survival (mo) 
Boston (11, 15) 1/24/59 Fraternal twin > 50 
2 Paris (16) 6/29/59 Fraternal twin >45 
3 Paris (17) 6/22/60 Unrelated 18 (Died) 
4 Paris (16) 12/19/60 Mother > 12 (Died) 
5 Paris (17) 3/12/61 Unrelated 18 (Died) 
6 Paris (16) 2/12/62 Cousin > 13 
7 Boston (19) 4/5/62 Unrelated 11 
Boston: Joseph E Murray (patients 1 and 7). Paris: Jean Hamburger (patients 2, 4. and 6). R Kiiss (patients 3 and 5). 
ertheless, the fraternal twin allografts functioned with-
out additional treatment for more than 2 decades. 
During the next 3 years (1960 to 1962), four more sur-
vivals of 1 year or longer were recorded in Paris after 
similar irradiation treatment, using kidneys from more 
genetically distant donors including two who were un-
relatedl6•17 (Table 2). The world's first two long-
surviving recipients of nonrelated kidneys were patients 
of Rene KuSS,17 a Paris urologist who in 1951 had de-
scribed the renal transplant operation that has been used 
worldwide ever since. 18 
In the next major step, Murrai9 achieved life-
supporting renal graft function for 17 months in a patient 
who was treated with azathioprine after receipt of a kidney 
from a genetically unrelated donor. The allograft was ob-
tained from a patient on cardiopulmonary bypass whose 
heart beat could not be restored. This seventh patient (Ta-
ble 2) provided the first example of prolonged survival un-
der drug immunosuppression only. The stage for pharma-
cologic immunosuppression had been set by extensive 
studies in dogs of 6-mercaptopurine and azathioprine by 
Roy Calne (first in London and subsequenclywith Murray 
in Boston), and by Charles Zukoski (with David Hume in 
Richmond). 
Other preclinical studies were done in surgicallabo-
ratories in Minneapolis, Denver, and elsewhere. Only 
about 5% of canine kidney recipients survived for as 
long as 100 days, but in a small subset of the long sur-
vivors, a state of drug-free alIa-graft acceptance devel-
oped in which kidney rejection did not occur for long 
periods, if at all, when treatment was stopped. This was 
subsequently observed with far greater frequency after 
liver replacement.2o 
The tantalizing possibility of emancipating patients 
from drug immunosuppression was suggested by two 
highly appreciable, but enigmatic phenomena observed 
in kidney recipients treated in Denver in 1962 to 1963.21 
The first finding was that kidney rejection was a regu-
larly reversible event instead of being inexorable, as had 
been previously thought. The second was that an allo-:-
graft, if protected by nonspecific multiple drug immu-
nosuppression, could induce what appeared to be vari-
able tolerance. 
In the Colorado patients, azathioprine was started 1 
to 4 weeks before the operation and continued as mono-
therapy afterward (Fig. 3, left). When rejection was di-
agnosed by a rise in serum creatinine, large doses of 
prednisone were added, but then withdrawn over several 
months after rejection was reversed. Although rejection 
occurred in essentially every patient, development of 
partial tolerance in many of the survivors was inferred 
from the rapidly declining need for treatment (Fig. 3, 
left). 
In fact, 9 (19%) of 46 allografts from familial donors 
transplanted during 1962 to 1963 functioned for the 
next 4 decades.22 The individual patients are depicted as 
horizontal bars in Figure 4. The important point is that 
all immunosuppression eventually was stopped in 7 of 
the 9 patients without rejection for periods ranging from 
6 to 40 years. Eight of the 9 patients are still alive and 
bear the longest surviving organ allografts in the world, 
all now 41 to 43 years posttransplantation. 
SEARCH FOR MECHANISMS 
What was the explanation for the unique collection of 
Denver patients, the occasional drug-free animals in the 
preclinical studies, and the lifetime tolerance of the fra-
ternal twins of 1959? The mystery deepened in 1966, 
when it was reported by Cordier and colleagues23 
in France and then in England by Peacock and 
Terblanche24, and by Calne and colleagues25 •26 that the 
liver can be transplanted in about 20% of outbred pigs 
without any treatment at all. None of the exceptional 
human or animal organ recipients, nor any of the rapidly 
growing population of human kidney recipients being 
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Figure 3. Left, empirically developed immunosuppression used for kidney transplant recipients at the University of 
Colorado in 1962 to 1963. Note the reversal of rejection with the addition of prednisone to azathioprine. More than 
a third of a century later, the crucial role of the timing of drug administration was clarified. Right, treatment revisions 
in immunosuppression made at the University of Colorado in December 1963 that unwittingly undermined basic 
mechanisms of tolerance induction. Pretreatment was deemphasized or eliminated, and high doses of prednisone 
were given prophylactically instead of as needed. 
maintained on immunosuppression had been given a 
bone marrow infusion. 
Graft-versus-host disease had never been seen despite 
the systematic use of organs from HLA-mismatched do~ 
nors. Taken together, these observations ostensibly ruled 
out leukocyte chimerism as a factor in organ engraft-
mene. In a nutshell, the seed planted by Medawar1,2 in 
1943 and nurtured a decade later by Billingham and 
Recipient Donor CR 
1 Sister <1.5 
2 Brother <1.5 
3 Mother <1.5 
4 Mother <1.5 
5 Mother 6.0 
6 Sister <1.5 
7 Gr. Aunt <1.5 
8 Father :<1.5 
9 Uncle <1.5 
Years Post Transplantation 
Figure 4. Current status of 9 (19%) at the 46 live donor kidney 
reCipients treated at the University of Colorado over an is-month 
period beginning in the autumn of 1962. Dark gray portion of the 
horizontal bars, immunosuppression; light gray portion, no immuno-
suppression. Four decades later, kidney function was normai in all 
but one of the nine patients. CR, serum creatinine. * Murdered: 
kidney graft normal at autopsy. (Reprinted tram: Starzl TE. Lessons 
of organ-induced tolerance learned from historic clinical experience. 
Transplantation 2004;77:926-929, with permission.) 
colleagues3 apparently had differentiated along two 
completely unrelated pathways: one of organ and the 
other of bone marrow transplantation (Fig. 5). An addi-
tional conclusion now was reached by group consensus 
that fundamentally different mechanisms must be in-
volved in the two kinds of engraftment. 
In effect, this conclusion detached organ transplanta-
tion from the scientific anchor of leukocyte chimerism 
that directly linked the mouse tolerance models and hu-
man bone marrow transplantation. With acceptance of 
Solid Organ Bone Marrow 
(Mad«war) 
Figure 6. The divergence of organ (left) and bone marrow transplan-
tation. The conclusion that the two kinds of transplantation involved 
different mechanisms of engraftment was the basis for an episte-
mologie collapse in transplantation immunology,27 
I 
. I 
I 
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the chimerism exclusionary premise, there was an epis-
temologic collapse, a "failure to understand."27 The 
enigma of organ engraftment was remanded to the basic 
research laboratories for resolution. MedawarB himself 
was puzzled.' In commenting on the frustrating search 
for the increasingly mystical mechanisms of organ allo-
engraftment, he concluded that, " ... the spectacle of a 
scientist locked in combat with the forces of ignorance is 
not an inspiring one if, in the outcomes, the scientist is 
routed." 
One of the scientists who tackled the problem was a 
young Philadelphia surgeon named Clyde Barker who 
joined forces with a member of the English holy trinity 
(Rupert Billingham) after Billingham migrated from 
England to the University of Pennsylvania in 1967. In 
1968, Barker and Billingham29 published a key contri-
bution to basic transplant immunology. This was the 
demonstration that skin grafts were not rejected if they 
were placed on an island of recipient skin that had been 
separated from lymphatic drainage (Fig. 6). With their 
elegant but simple experiment, they had elucidated one 
of the two mechanisms of allografr acceptance, namely 
the failure of the immune system to recognize the pres-
FIgure 6. Failure of the immune system to reject a skin allograft 
whose mobile antigen is prevented from reaching host lymphoid 
organs. (Reprinted from: Barker C. The role of afferent lymphatics in 
the rejection of skin homografts. J Exp Med 1968;128:197-221, 
with permission.) 
J Am Coli Surg 
ence of antigen that does not reach host lymphoid or-
gans, ie, "immune ignorance." 
More than a quarter of a century passed before the 
validity and importance of this mechanism were fully 
established. Clonal exhaustion-deletion, the other sem-
inal mechanism of alloengraftment, also was a casualty 
of group think. In 1969, the concept of exhaustion and 
deletion of the clonal antidonor response (also called 
"clone stripping"), was depicted schematically to explain 
liver and other kinds of organ engraftment (Fig. 7).30 
With dismissal of the two simple and easily under-
stood mechanisms of exhaustion-deletion and immune 
ignorance, alternative mechanisms of alloengraftment 
abounded, too numerous to do more than list (Table 3). 
The "proof of principle" period, during which the 
feasibility of clinical organ transplantation was estab-
lished, ended in 1968 with a downside. The bright note, 
of course, was the birth of a new surgical specialty (organ 
transplantation) and of a new medical discipline (bone 
marrow transplantation). The dark legacy was the intel-
lectual divorce of bone marrow and organ transplanta-
tion. There also was a therapeutic legacy: a modified 
version of the treatment strategy that had been devel-
oped originally with azathioprine and prednisone (Fig. 
3, left). The principal changes were in drug timing and 
quantity (Fig. 3, right). 
Beginning in 1964, large prophylactic doses of pred-
nisone were given from the time of operation instead of 
administering steroids only when needed. This strategy 
of heavy prophylactic immunosuppression with azathio-
prine and prednisone was used at most centers until well 
into the 19805, without or with the antilymphocyte 
globulin, which was introduced clinically in 1966.31 In 
addition, pretreatment with azathioprine, which had 
been used in the 1962 to 1963 patients, was deempha-
sized or abandoned (Fig. 3, right). Implications of these 
modifications were not recognized until the end of the 
20th century. 
MATURATION OF TRANSPLANTATION 
The years between 1969 and 1980 bracketed a bleak 
period. In the view of critics, the heavy mortality and, 
particularly, the devastating morbidity caused by, steroid 
dependence, made organ transplantation (even of kid-
neys) as much a disease as a treatment. Prospects im-
proved dramatically with the clinical introduction of 
cyclosporine in 1980,32.33 followed a decade later by ta-
crolimus.34•35 The new drugs were associated with step-
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FIgure 7. A 1969 hypothesis of allograft acceptance by clonal exhaustion. Antigen presentation was depicted 
through the macrophages rather than dendritic cells (which had not yet been described). A gap in this hypothesis 
was the failure to stipulate the location of antigen recognition and immune activation. (Reprinted from: Starzl TE. 
Experience in hepatic transplantation, Philadelphia, WB Saunders Co, 1969, with permission.) 
wise improvements with all organs, but their impact was 
most conclusively demonstrated with liver and heart 
transplantation. 
generations. Used in various combinations, the better 
drugs fueled the golden age of transplantation of the 
1980s and 1990s. Acute rejection became almost a non-
problem. But the unresolved issues now were chronic 
rejection, risks of immunosuppression, and drug-
specific toxicity. 
Because more potent baseline or adjunct agents be-
came available, they were simply folded into the mod-
ified formula of heavy prophylactic immunosuppres-
sion that had been inherited from the previous 
Table 3. Mechanisms of Acquired Tolerance 
and Alloengraftment 
Seminal mechanisms 
Clonal exhaustion-deletion 
Immune ignorance 
Alternative mechanisms 
S pedal cells ~ T-regulatory, suppressor, 
veto 
Antibodies ~ Idiotypic, enhancing 
Cyrokine ~ Self-perpetuating profiles 
Graft secretions ~ Soluble HIA antigens 
Antigen presentation ~ Defective or deviant 
Anergy ~ Absence of second signal 
RELATION OF ALLOENGRAFTMENT 
TO TOLERANCE 
I have emphasized that organ. engraftment was attrib-
uted until recently to mechanisms that did not involve 
either the presence or role ofleukocyte chimerism. It was 
known that organs contain large numbers of passenger 
leukocytes and that these "nonparenchymal cells" were 
largely replaced in the successfully transplanted organ 
allograft by recipient leukocytes of the same lineages 
(Fig. 8A). The missing donor cells were thought to have 
undergone immune destruction with selective sparing of 
the specialized parenchymal cells. In mirror image, the 
ideal result in the bone marrow transplant recipient had 
I 
I 
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Figure 8. Old (A,B) and new (C,D) views of transplantation recipients. (A) The early conceptualization of immune 
mechanisms in organ transplantation in terms of a unidirectional host-versus-graft (HVG) response. Although this 
readily explained organ rejection, it limited possible explanations of organ engraftment. (B) Mirror image of (A), 
depicting the early understanding of successful bone marrow transplantation as a complete replacement of the 
recipient immune system by that of the donor, with the potential complication of an unopposed lethal unidirectional 
graft-versus-host (GVH) response, ie, rejection of the recipient by the graft. (C) Our current view of bidirectional and 
reciprocally modulating immune responses of coexisting immune competent cell populations. Because of variable 
reciprocal induction of deletional tolerance, organ engraftment was feasible despite a usually dominant HVG 
reaction. The bone silhouette in the graft represents passenger leukocytes of bone marrow origin. (D) Our currently 
conceived mirror image of (C) after successful bone marrow transplantation. Recipients' cytoablation has caused 
a reversal of the size proportions of the donor and recipient populations of immune cells. 
been perceived to be complete replacement of recipient 
immune cells (ie, total hematolymphopoietic chimer-
ism) (Fig. 8B). 
A flaw in the overarching dogma shown in Figures 8A 
and 8B was revealed in the early 1990s with our discov-
ery of small numbers of donor cells (micro chimerism) in 
the tissues or blood of long-surviving organ recipi-
ems36.37 (Fig. 8e). At about the same time, it was inde-
pendently demonstrated in Seattle that (here was essen-
tially always a small residual population of recipient 
hematolymphopoietic cells in bone marrow recipients, 
who previously had been considered to have complete 
leukocyte chimerism38 (Fig. 8D). Now it was evident 
that organ engraftment and bone marrow cell engraft-
ment were mirror image versions of leukocyte chimer-
ism, differing primarily in the reversed proportion of 
donor and recipient cells (compare Figs. 8e and BD).39 
The microchimeric cells in organ recipients clearly 
were progeny of donor precursor or pluripotent stem 
cells that had survived a double immune reaction years 
or decades earlier, just after transplantation. Both organ 
and bone marrow cell engraftment now could be ex-
plained by" ... responses of coexisting donor and recip-
ient cells, each to the other, causing reciprocal clonal 
exhaustion, followed by peripheral clonal deletion."36.37 
Exhaustion-deletion of the host-versus-graft response 
was the reason for reversal of rejection and development 
of variable tolerance that had been first observed in kid-
ney recipients 30 years earlier, and eventually in all other 
kinds of organ recipients. 
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Figure 9. Contemporaneous host-versus-graft (HVG) (upright curves) 
and graft-versus-host (GVH) (inverted curves) responses after organ 
transplantation. In contrast to the usually dominant HGV reaction of 
organ transplantation, the GVH reaction usually is dominant after 
bone marrow cell transplantation to the irradiated or otherwise 
immunodepressed recipient. Therapeutic failure with either type of 
transplantation implies the inability to control one, the other, or both 
of the contemporaneous responses with a protective umbrella of 
immunosuppression. (Reprinted from: Starzl TE. Antigen localization 
and migration in immunity and tolerance. New Engl j Med 1998; 
339:1905-1913, with permission.) 
The host-versus-graft response (upright curve in the 
middle panel of Fig. 9) was the dominant one in most 
cases of organ transplantation, but with the occasional 
exception of graft-versus-host disease (the inverted 
curve). Host irradiation or other methods of cytoabla-
tion for conventional bone marrow transplantation sim-
ply transferred immune dominance from the host to the 
graft, explaining the high risk of graft-versus-host disease 
in bone marrow recipients.· All of the major differences 
between the two kinds of transplantation were caused by 
recipient cytoablation. 
In their classic studies of 1968, Barker and Billing-
ham29 had demonstrated that transplant antigen that did 
not reach host lymphoid organs was not recognized to be 
present (immune ignorance). The only mobile antigen 
in organs consisted of passenger leukocytes. In the cur-
rent paradigm, selective migration of these cells to host 
lymphoid organs is an absolute requirement for the sem-
inal tolerance (and engraftment) mechanism of clonal 
exhaustion-deletion of the antigraft response (Fig. 10). 
The early Barker-Billingham observations, as:: it 
turned out, had an extra dimension. After 2 or 3 weeks, 
cells that have escaped destruction in the host lymphoid 
organs or have bypassed them move to protected non-
lymphoid sites where they can be forgotten by the im-
mune system. This more subtle version of immune ig-
norance is thought to be essential for perpetuation of the 
low-level microchimerism of organ recipients and main-
tenance of the exhaustion-deletion induced at the outset 
in complex ways that are discussed elsewhere.40-42 Suffice 
it to say here, the spectrum of clinical outcomes after 
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Figure j.O. Clonal exhaustion-deletion, the seminal mechanism of 
organ engraftment, and of acquired tolerance. Persistence of some 
donor cells is a prerequisite for maintenance of the variable dele-
tional tolerance induced by the initial surge of donor cells. (Re-
printed from': Starzl TE. The saga of liver replacement, with particular 
reference to the reciprocal influence of liver and kidney transplan-
tation. j Am Coli Surg 2002;195:587-610, with permission.) 
both kinds of transplantation depended on variable 
combinations of clonal exhaustion-deletion and im-
mune 19norance. 
After an estrangement of more than a third of a cen-
tury, the conceptual separation of bone marrow and or-
gan transplantation was ended. How this unified view of 
transplantation fit into the larger framework of general 
immunology was considered subsequently in a review 
written in collaboration with Rolf Zinkernagel, 40 whose 
1996 Nobel Prize (with Peter Doherty) was awarded for 
basic studies of the adaptive immune response to non-
cytopathic pathogens.43,44 The review clarified the anal-
ogies between the immunologic mechanisms of trans-
plantation vis-a.-vis those of infections, with particular 
emphasis on the regulation of these mechanisms by the 
migration and localization of the respective antigens. 
CLINICAL IMPLICATIONS 
Although the mystery of alloengraftment was solved, it 
was not clear how the insight into immunologic mech-
anisms could be used to improve the treatment of trans-
plant recipients? This question was addressed in a second 
review in 2001.41 By now, it required little imagination 
to envision how the heavy multidrug immunosuppres-
sion given in most centers from the time of transplanta-
tion coUld systematically inhibit the seminal tolerance 
mechanism of clonal exhaustion-deletion and thereby 
commit the recipient to unnecessarily high longrerm 
immunosuppression to prevent emergence of the subop-
timally deleted antidonor clone (Fig. 11, top). 
We suggested that this undesirable consequence could 
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Figure 11. Top: If clonal activation is unduly inhibited by excessive 
posttransplant immunosuppression, exhaustion-deletion is variably 
precluded, and longterm graft survival is unnecessarily high immu-
nosuppression. Bottom: Conversion of rejection (thick dashed ar-
row) to an immune response that can be exhausted and deleted by 
combination of pretreatment and minimallstic posttransplant immu-
nosuppression. GVH, graft-versus-host; HVG, host-versus-graft; Tx, 
transplantation. (Reprinted from: Starzl TE. Tolerogenic immunosup-
pression for organ transplantation. Lancet 2003;361:1502-1510, 
with permission.) 
be minimized by application of two therapeutic princi-
ples (Fig. 11, bottom). The frrst was to lower the antic-
ipated donor-specific response into a more readily delet-
able range by reducing the overall immune reactivity of 
the recipient before rather than after the arrival of the 
allograft. The second principle was to administer only as 
much posttransplant immunosuppression as is necessary 
to prevent or quickly control rejection. . . "-_.'-' 
The application of these principles is exemplified by 
the course shown in Figure 12 of a 63-year-old woman 
who received a cadaver kidney in August 2001. In this 
patient and in more than 1,000 recipients of different 
kinds of organs since 2001, pretreatment has been done 
with an infusion of an antilymphoid antibody, followed 
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Figure 12. Course of a cadaver kidney recipient in July 2001, after 
pretreatment with 5 mgjkg antilymphocyte globulin. Biopsy-proved 
rejection in the third week was treated with infusions of 1.0 and 0.5 
prednisone. Daily tacrolimus (Tac.) (fully shaded area) was begun on 
the day after operation and spaced to every other day or longer 
intervals after 6.5 months. Open balls in the upper panel indicate 
trough levels oftacrolimus. Tacrolimus doses have been given once 
per week for almost 3 years. (Reprinted from: Starzl TE. Chimerism 
and tolerance in transplantation. Proc Natl Acad Sci 2004; 
101[Suppl 2]:14607-14614, with permission.) 
by minimum posttransplant immunosuppression with 
tacrolimus mono therapy (see Fig. 12 caption). With this 
strategy, the complications of longterm immunosup-
pression have been considerably reduced with survival 
results equivalent to those under conventional heavy 
imm unosuppression. 45-48 
VIEW OF THE FUTURE 
Although completely drug-free tolerance undoubtedly 
will be most easily achieved in recipients of HLA-
matched organs, our already extensive experience sug-
gests that the burden of chronic immunosuppression 
can be systematically reduced in the vast majority of 
patients with the foregoing mechanism-driven approach 
to management. Xenotransplantation will have to be 
developed within the same immunologic framework, 
but this will require the creation with transgenic tech-
_s_l_fK_O_M_1_I_k_oK_O_I_A_u~g_us_t_O_M_M_R ________________________________ ~p~ta~1 Mystique of Organ Transplantation 169 
nology of a better interspecies tissue match. Although 
the all-important step of knocking out the a-Gal gene in 
pigs has been accomplished,49 it is not yet known what 
additional changes must be made before porcine organs 
can be reliably transplanted to humans. Where stem cell 
biology will fit into future transplantation plans remains 
unknown, bur it clearly will have to conform to the same 
immunologic rules. 
Whatever the future holds, progress will require the 
continued collaboration of basic and clinical scientists. 
"What does this really mean? I will conclude by express-
ing my belief that the distinction of basic science from 
the science of clinical medicine is artificial. No advance 
in surgery ever illustrated this more clearly than the 
phoenix-like rise of clinical organ transplantation during 
which truly dominant discoveries came from the labora-
tory (bench to bedside) and equally important break-
throughs drove the equation in the opposite direction 
(bedside to bench). The magic was in the mix. 
Acknowledgment: Ms Terry Mangan provided invaluable as-
sistance in preparation of the Ravdin Lecture and the deriva-
tive article. 
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